AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03787992
Drug: Placebo Gefitinib 250 mg
RxNorm normalized name: gefitinib 250 MG
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT03787992
Drug: Gefitinib 250 mg
RxNorm normalized name: gefitinib 250 MG
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT02005822
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
Trial: NCT00631878
Drug: Pagibaximab (formerly BSYX-A110)
RxNorm normalized name: Pagibaximab
DrugBank: Pagibaximab (DB17786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
Trial: NCT01250886
Drug: Lactated Ringer's solution
RxNorm normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
Trial: NCT02651090
Drug: Sonazoid
RxNorm normalized name: Sonazoid
DrugBank: Perflubutane (DB12821)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Sonazoid enhanced ultrasound to non enhanced CT
Trial: NCT01172379
Drug: E2007
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental 1 Drug: E2007~0.5 mg 1 tablet per day
Trial: NCT01172379
Drug: E2007
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental 2 Drug: E2007~1.0 mg 1 tablet per day
Trial: NCT01172379
Drug: E2007
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: E2007~2.0 mg 1 tablet per day
Trial: NCT01250886
Drug: Normal saline solution
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
Trial: NCT01250886
Drug: Acetate Ringer's solution
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
Trial: NCT03200782
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
Trial: NCT03200782
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
Trial: NCT00004918
Drug: Montanide ISA 51 VG
RxNorm normalized name: Montanide ISA 51 VG
DrugBank: Incomplete Freund's adjuvant (DB17475)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT01848145
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of \>= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE \>= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
Trial: NCT04426695
Drug: REGN10933+REGN10987 combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) single dose
Trial: NCT02688647
Drug: Belumosudil
RxNorm normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01111305
Drug: Reslizumab
RxNorm normalized name: Reslizumab
DrugBank: Reslizumab (DB06602)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01111305
Drug: Diethylcarbamazine
RxNorm normalized name: Diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04216082
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Trial: NCT00694980
Drug: rhuMAb Beta7
RxNorm normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous and subcutaneous escalating doses
Trial: NCT02212769
Drug: Losartan 50mg
RxNorm normalized name: LOSARTAN 50MG TAB
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50mg once daily for 7 days
Trial: NCT02212769
Drug: DW1029M 1200mg and Losartan 50mg
RxNorm normalized name: Losartan Potassium and Hydrochlorothiazide Tablets
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
Trial: NCT03492697
Drug: PF-06882961 Immediate Release Tablet
RxNorm normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release Tablet
Trial: NCT03492697
Drug: PF-06882961 Controlled Release Tablet (long)
RxNorm normalized name: LONG PEPPER
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled Release tablet (long)
Trial: NCT03492697
Drug: PF-06882961 Controlled Release Tablet (short)
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled Release tablet (short)
Trial: NCT03492697
Drug: PF-06882961 Immediate Release Solution
RxNorm normalized name: taurine
DrugBank: PF-06882961 (DB16043)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PF-06882961 Immediate Release solution
Trial: NCT00772551
Drug: Raltegravir and ezetimibe
RxNorm normalized name: atorvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
Trial: NCT00772551
Drug: Ezetimibe and raltegravir
RxNorm normalized name: atorvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
Trial: NCT00955266
Drug: Calcium Chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
Trial: NCT04187196
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol will be given at an initial dose of 0.8 mg/kg followed by 20 mg every minute after 2 minutes, if adequate sedation is not achieved
Trial: NCT04187196
Drug: Methohexital
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital will be given at an initial dose of 0.5 mg/kg, followed by 10 mg every minute after 2 minutes, if adequate sedation is not achieved
Trial: NCT03317119
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02348528
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02348528
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02499393
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous infusion of magnesium sulphate
Trial: NCT04473651
Drug: Lu AG06479
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, orally (Part A and B)
Trial: NCT03407872
Drug: Esketamine DPI
RxNorm normalized name: esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
Trial: NCT03407872
Drug: Esketamine DPI
RxNorm normalized name: esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high.
Trial: NCT03407872
Drug: Esketamine DPI
RxNorm normalized name: esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high.
Trial: NCT00557791
Drug: Bevasiranib
RxNorm normalized name: Bevasiranib
DrugBank: Bevasiranib (DB06642)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
Trial: NCT00557791
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
Trial: NCT01095120
Drug: Tesetaxel
RxNorm normalized name: Tesetaxel
DrugBank: Tesetaxel (DB12019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects in Cohort A, a flat dose of 40 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the Cycle 1 flat dose may be increased by 5 mg in Cycle 2, and the Cycle 2 flat dose may again be increased by 5 mg in Cycle 3.~For subjects in Cohort B, a flat dose of 50 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the dose may be increased by 10 mg in Cycle 2.~For subjects in Cohort C, a dose of 27 mg/m2 will be administered in Cycle 1. In subsequent cycles, depending on tolerability, the dose will be increased to 35 mg/m2 in Cycle 2.
Trial: NCT01813318
Drug: Acamprosate
RxNorm normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
Trial: NCT01420081
Drug: PF-05212384
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 154mg IV weekly
Trial: NCT00837759
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00837759
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00837759
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00837759
Drug: GAD65 (Diamyd)
RxNorm normalized name: Recombinant human GAD65
DrugBank: rhGAD65 (DB04963)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00734071
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Encapsulated vortioxetine immediate-release tablets
Trial: NCT01331967
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15-30mg, once daily for 9 months
Trial: NCT00505947
Drug: infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: infliximab 5 mg/Kg body weight by intravenous infusion
Trial: NCT03497364
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 % bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection according to the height of subjects (1.7 ml for 173\~174cm, 1.65 ml for 170\~172cm, 1.6 ml for 168\~169cm, 1.55 ml for 165\~167cm, 1.5 ml for 163\~164cm, 1.45 ml for 160\~162cm, 1.4 ml for 158\~159cm, 1.35 ml for 155\~157cm, 1.3 ml for 153\~154cm, 1.25 ml for 150\~152cm, 1.2 ml for 148\~149cm)，1.15 ml for 145\~147cm).
Trial: NCT03497364
Drug: ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 % ropivacaine (1% ropivacaine (1.5 ml) + cerebrospinal fluid (1.5 ml)) was injection according to the height of subjects (2.300 ml for 173\~174cm, 2.225 ml for 170\~172cm, 2.15 0ml for 168\~169cm, 2.075 ml for 165\~167cm, 2.000 ml for 163\~164cm, 1.925 ml for 160\~162cm, 1.850 ml for 158\~159cm, 1.775 ml for 155\~157cm, 1.700 ml for 153\~154cm, 1.625 ml for 150\~152cm, 1.55 0ml for 148\~149cm, 1.475 ml for 145\~147cm)
Trial: NCT02045693
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02045693
Drug: BMS-791325
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02045693
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02045693
Drug: Naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03559699
Drug: AG-348
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1.
Trial: NCT00340379
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target dosage 120-160mg/day based on tolerance
Trial: NCT00340379
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target dosage 150-200mg/day based on tolerance.
Trial: NCT00340379
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target dosage 6-8mg/day based on tolerance.
Trial: NCT01330966
Drug: pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
Trial: NCT00649831
Drug: Amoxicillin/clavulinic acid
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
Trial: NCT01650740
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg daily x 1 week followed by 60 mg daily
Trial: NCT00397332
Drug: Alefacept
RxNorm normalized name: Alefacept
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM Alefacept
Trial: NCT03509324
Drug: Insulin LISPRO
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: receive short-term insulin pump therapy by using insulin LISPRO, continue treatment for 7 more days when euglycemia achieved
Trial: NCT00778973
Drug: sertraline 100 mg tablets
RxNorm normalized name: sertraline 100 MG
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00268645
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00955058
Drug: OCP
RxNorm normalized name: EoCP - Eosinophil cationic protein
DrugBank: Eosin (DB13706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily For 3 months
Trial: NCT02552303
Drug: Armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active medication
Trial: NCT01830790
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 100mg Sildenafil citrate
Trial: NCT04534842
Drug: SYNB1934
RxNorm normalized name: SYNB1934
DrugBank: Labafenogene marselecobac (DB17618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
Trial: NCT00056446
Drug: Vatalanib
RxNorm normalized name: Vatalanib
DrugBank: Vatalanib (DB04879)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00218543
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
Trial: NCT04524403
Drug: Miricorlilant
RxNorm normalized name: Miricorilant
DrugBank: Miricorilant (DB16234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing
Trial: NCT04524403
Drug: Miricorlilant
RxNorm normalized name: Miricorilant
DrugBank: Miricorilant (DB16234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing
Trial: NCT03545711
Drug: Anlotinib Hydrochloride with Irinotecan
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.
Trial: NCT01176565
Drug: Intravenous nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present.
Trial: NCT03104842
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antibody Intravenous
Trial: NCT03104842
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT03104842
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsel
Trial: NCT03104842
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsel